Evidence map›Paper›PMID 39775518›Full record

ArticleJournal of nephrology2025

Association between urate-lowering therapy and kidney failure in patients with chronic kidney disease.

Agathe Mouheb, Oriane Lambert, Natalia Alencar de Pinho, Christian Jacquelinet, Maurice Laville, Christian Combe, Denis Fouque, Luc Frimat, Ziad A Massy, Solène M Laville and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Agathe MouhebPharmacoepidemiology Unit, Department of Clinical Pharmacology, Amiens-Picardie University Medical Center, CHU Amiens-Picardie, Rond-Point du Professeur Christian Cabrol, 80054, Amiens Cedex, France.
Oriane LambertCentre for Research in Epidemiology and Population Health (CESP), INSERM, UMRS 1018, Université Paris-Saclay, Université Versailles Saint Quentin, 94807, Villejuif, France.
Natalia Alencar de PinhoCentre for Research in Epidemiology and Population Health (CESP), INSERM, UMRS 1018, Université Paris-Saclay, Université Versailles Saint Quentin, 94807, Villejuif, France.
Christian JacquelinetBiomedicine Agency, 93212, Saint Denis, France.
Maurice LavilleUniversité de Lyon, CarMeN INSERM 1060, 69008, Lyon, France.
Christian CombeService de Néphrologie Transplantation Dialyse Aphérèse, Centre Hospitalier Universitaire de Bordeaux, 33000, Bordeaux, France.
Denis FouqueUniversité de Lyon, CarMeN INSERM 1060, 69008, Lyon, France.
Luc FrimatNephrology Department, CHRU de Nancy, 54000, Vandoeuvre-lès-Nancy, France.
Ziad A MassyCentre for Research in Epidemiology and Population Health (CESP), INSERM, UMRS 1018, Université Paris-Saclay, Université Versailles Saint Quentin, 94807, Villejuif, France.
Solène M LavillePharmacoepidemiology Unit, Department of Clinical Pharmacology, Amiens-Picardie University Medical Center, CHU Amiens-Picardie, Rond-Point du Professeur Christian Cabrol, 80054, Amiens Cedex, France.
Sophie LiabeufPharmacoepidemiology Unit, Department of Clinical Pharmacology, Amiens-Picardie University Medical Center, CHU Amiens-Picardie, Rond-Point du Professeur Christian Cabrol, 80054, Amiens Cedex, France. liabeuf.sophie@chu-amiens.fr.ORCID http://orcid.org/0000-0001-5384-9006
Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyperuricemia is a hallmark of gout and a suspected risk factor for the progression of chronic kidney disease (CKD). However, the impact of urate-lowering therapy on CKD progression is subject to debate. The objective of the present study was to describe the prevalence of inappropriate urate-lowering therapy prescriptions and evaluate the association between urate-lowering therapy prescription and the progression of kidney disease in patients with CKD.

methodsCKD-REIN is a French, nationwide, prospective cohort of 3,033 nephrology outpatients with CKD (eGFR < 60 mL/min/1.73 m

resultsAt baseline, 987 of the 3009 patients included in this study (median age: 69; men: 66%) were receiving urate-lowering therapy; 396 of these 987 patients were receiving an inappropriate prescription with regard to their kidney function. During a 5-year follow-up period, 70% of the 396 urate-lowering therapy prescriptions remained inappropriate. In the propensity score-matched cohort (n = 674), 136 patients started KRT. Compared with non- urate-lowering therapy use, urate-lowering therapy use was not significantly associated with a slowing in CKD progression, regardless of the definition used (HR

conclusionsOur real-world data emphasized the lack of reassessment of urate-lowering therapy prescriptions in patients with CKD. Urate-lowering therapy was not associated with a slowing of CKD progression.

Indexed as

AllopurinolFebuxostatGout SuppressantsHyperuricemiaInappropriate PrescribingRenal Insufficiency, ChronicUric AcidAgedDisease ProgressionFemaleFranceGlomerular Filtration RateHumansMaleMiddle AgedPropensity ScoreAllopurinolFebuxostatGout SuppressantsUric AcidChronic kidney diseaseDisease progressionDrug useInappropriate prescribingPharmacoepidemiologyUrate-lowering therapy

Identifiers

PMID39775518

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.